Opioid-Induced Constipation (OIC) treatment market is anticipated to grow at a significant CAGR of 9.3% during the forecast period (2024-2031). The market growth is attributed to accelerated efforts for drug approval, an increase in the number of prescriptions for opioid analgesics, increased funding for the investigation and development of novel therapies, and a surge in the development of biologics. The market for opioid-induced constipation therapy is expected to grow in the future owing to the rise in the administration of opioids for pain, both cancer-related and not. Pain is managed with a class of potent analgesics named opioids. Owing to several circumstances, their use has significantly increased in recent years. The rise in the geriatric population is resulting in a rise in chronic and oncologic diseases, necessitating the use of pain management techniques. Consequently, there has been a notable global rise in the prescription of opioids.
Browse the full report description of “Opioid-Induced Constipation Treatment Market Size, Share & Trends Analysis Report by Drug Class (Laxatives, Peripherally Acting Mu-opioid Receptor Antagonists, Serotonin Receptor Agonists, and Prostaglandin), by Administration Route (Oral and Parenteral), and by Distribution Channel (Hospital Pharmacies, Online Pharmacies and Retail Pharmacies) Forecast Period (2024-2031)” at https://www.omrglobal.com/industry-reports/opioid-induced-constipation-treatment-market
According to the National Center for Biotechnology Information, in August 2023, Opioid-induced constipation (OIC) accounts for between 40.0%-60.0% of patients without cancer receiving opioids. Laxatives must be started at the same time as the opioid to prevent OIC. Once the disorder is established, treatment involves both pharmacological and nonpharmacological therapies. The GI tract's peristalsis and stomach emptying are known to be inhibited by opioid prescriptions, which causes a delay in medicine absorption and an increase in fluid absorption. Constipation and stool hardness are caused by low intestinal fluid levels.
Recent Development
Market Coverage
• The market number available for – 2023-2031
• Base year- 2023
• Forecast period- 2024-2031
• Segment Covered-
o By Drug Class
o By Administration Route
o By Distribution Channel
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- AstraZeneca, Mallinckrodt Pharmaceuticals, Nektar Therapeutics, Pfizer Inc., and Takeda Pharmaceutical Co. Ltd. among others.
Key questions addressed by the report.
Global Opioid-Induced Constipation Treatment Market Report Segment
By Drug Class
By Administration Route
By Distribution Channel
Global Opioid-Induced Constipation Treatment Market Report Segment by Region
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/opioid-induced-constipation-treatment-market